Printer Friendly

Articles from M2 Pharma (September 4, 2014)

1-16 out of 16 article(s)
Title Author Type Words
Abbott gains CE Mark for FreeStyle Libre glucose monitoring system. 225
Asuragen, Labceutics disclose study data on standardisation of BCR-ABL1 testing in CML patients. 341
BioLegend acquires Covance Antibody Services. 128
Celator Pharmaceuticals names Michael Dougherty as board chair. 134
Cell Marque signs marketing agreement with Abcam for IVD IHC RabMab antibodies. 147
EMD Serono Research and Development Institute signs collaborative research agreement with Massachusetts General Hospital. 155
Knight Therapeutics signs asset purchase agreement with Orphan Canada. 117
LabCorp launches Enlighten Health Genomics division. 187
Macrocure completes patient enrolment in double-blind, Phase III clinical trial of CureXcell. 193
Myriad Genetics' myRisk Hereditary Cancer test improves by 46% detection of cancer-causing mutations. 353
Palatin Technologies and Richter enter into license agreement for FSD bremelanotide in Europe and other selected countries. 251
Regeneron Pharmaceuticals applies marketing authorisation application for EYLEA Injection for macular edema following BRVO in Japan. 216
RegeneRx reports USD1m under product license and stock purchase agreement with G-treeBNT Co. 126
Teva unveils generic Baraclude tablets, 0.5mg and 1mg, in the US. 106
Thermo Fisher Scientific launches Ion AmpliSeq Transcriptome Solution. 254
US subsidiary of Lundbeck launches Northera (droxidopa) capsules in US. 138

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters